Exclusive: Germany’s Stada buys 15 GSK consumer health brands
FRANKFURT (Reuters) – Private equity-backed generic drugmaker Stada STAGn.D said it has agreed to buy 15 consumer healthcare products from…
Vectura, Sandoz win ruling on inhaler packaging case against GSK
(Reuters) – Vectura Group said on Friday a British court had ruled in its favor on the packaging of a…
GSK builds oncology pipeline as drug shown to help myeloma patients
(Reuters) – GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out…
GSK pharma head flags need for speed in high-pressure drug market
LONDON (Reuters) – Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford…
UK’s Vectura wins patent infringement case against GlaxoSmithKline in U.S
(Reuters) – British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline…
Long-acting injection a shot in the arm for GSK’s HIV business
LONDON (Reuters) – A long-acting injection developed by GlaxoSmithKline (GSK.L) and given once a month has proved as effective as…
GSK’s new R&D head bets on genetics with $300 million 23andMe deal
LONDON (Reuters) – GlaxoSmithKline’s new research boss aims to turbo-charge the British group’s drug discovery engine with a $300 million…
Clamor for GSK shingles shot points to bigger profits
LONDON (Reuters) – GlaxoSmithKline is facing “unprecedented” demand for its new shingles vaccine Shingrix, suggesting the product could be a…
GSK’s two-drug HIV treatment meets main goal in late stage studies
(Reuters) – GlaxoSmithKline’s two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies,…